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A R T I C L E   I N F O A B S T R A C T 
Since 1995, the European Medicines Agency (EMA) has progressed from 
harmonising regulation for human and veterinary medicines across the European 
Union Member State national competent authorities, to galvanising one of the most 
successful cooperative initiatives for regulation globally.  Although the EMA is the 
focal point for stakeholders, regulation is delivered through the European 
medicines regulatory network, in which national authorities, like the UK’s 
Medicines & Healthcare products Regulatory Agency (MHRA), contribute.  As 
with any collaboration, contributions by individual members vary, and the MHRA 
has been noted as an innovative and highly productive member of the network.  
Progress in regulation not only in Europe – but also around the world through 
convergence – can be attributed to this unique European cooperation.  The decision 
by the UK to leave the European Union threatens to mark the end of this 
cooperation; we argue here that the best decision is to maintain regulatory 
cooperation under new structures. 
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REGULATORY HARMONY  
In 2015, we celebrated the 20th Anniversary of the 
European Medicines Agency (EMA), applauding the 
success of a European collaboration in regulation of 
human and veterinary medicines that was unique in 
the world.  However, the origins of the European 
regulatory system go far beyond the 1995 launch 
date of the EMA.  It began in a shared concern, 
prompted by tragedies around the world, that 
effective regulation of medicines was essential to 
deliver effective innovation in treatment and patient 
safety. 
In Europe, harmonisation of regulation for medicines 
began with an EEC Directive in 1965 (65/65/EEC) 
and was extended in two further Directives 
specifying standards, law, regulation and 
administrative requirements in 1975 (75/318/EEC 
and 75/319/EEC) (Rägo and Santoso 2008). These 
Directives provided the basis for the forerunner to 
the EMA: the Committee on Proprietary Medicinal 
Products (CPMP).  A multistate procedure was 
established to allow countries to mutually recognise 
each other’s regulatory decisions, to facilitate 
production and use of medicines across the 
Community.  The decade following, a procedure was 
further agreed that allowed centralised decision 
making for regulatory review.  All of these features 
are now fully embodied in the work of the European 
medicines regulatory network and visible in the 
EMA as an agency “that protects public and animal 
health in 28 EU Member States, as well as the 
countries of the European Economic Area, by 
Expert Opinion 
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ensuring that all medicines available on the EU 
market are safe, effective and of high quality” (EMA 
2017a). 
The early decades of the European medicines 
regulatory network were a process of establishing 
regulatory harmonisation across the European 
Member States.  In regulation, ‘harmonisation’ has a 
very particular meaning: that it is a process by which 
the interpretation and/or application of technical 
guidelines can be made uniform or mutually 
compatible (Tominaga 2015). Harmonisation of 
regulations is a challenging task, and experts have 
noted that it requires science-based dialogue, 
consensus and a limited number of players that have 
a comparable regulatory and technical capability and 
are committed to implementing the products of 
harmonisation (Lustig and Weisfeld 2013). 
In the 20th anniversary year of the EMA, the focus 
was on the future, targeting the innovation in 
regulatory science that would need to accompany the 
innovations in drug development as well as the 
growing global health challenges we face.  In the 
Network Strategy to 2020, the agenda was to 
advance the scientific rigour and effectiveness of 
regulatory assessment but also to find efficiencies 
and better ways of working.  New medical 
technologies and breakthroughs in 
pharmacogenomics challenge existing models for 
regulation, and the EU regulators mapped out their 
approach to address these.  Also figuring in the 
Strategy was the desire to optimise the operation of 
the European medicines regulatory network itself, 
looking to improve through “efficient and cost-
effective procedures” and minimising “as much as 
possible the administrative burden for the 
pharmaceutical industry commensurate with public 
and animal health” (EMA 2015). 
Just one year later, the United Kingdom was to take a 
decision that has threatened to mark the end of this 
harmonised regulatory system in Europe.  Over 
decades, this regulatory system has enabled markets 
and production to integrate across the European 
Member States, and this is particularly true for 
medicines, where the multi-step process of 
production and distribution can take a medicine 
across many country borders until it reaches the 
patient.  Maintaining supply is a critical issue for the 
immediate future; maintaining regulatory 
harmonisation is a longer term priority. 
INDUSTRY RESPONDS 
The global pharmaceutical industry is used to having 
to balance very long term and high risk investments 
in the discovery, development, manufacture, 
regulation and provision of its medicines in an 
uncertain world.  In that respect, the UK’s decision to 
leave the EU was certainly a novel and considerable 
challenge for our industry to plan, but dealing with 
uncertainty and change is not new.  Our response 
was to undertake a detailed situation analysis and 
review, much of which was already in draft as 
companies anticipated the risks of the Referendum.  
We also began the considerable work of exploring 
and discussing the details across companies and 
across the wider life sciences sector.   The Association 
of the British Pharmaceutical Industry (ABPI) joined 
with the BioIndustries Association (BIA) to lead this 
process, at the request of the UK Ministerial Industry 
Strategy Group (GovUK 2017). 
We worked over the summer of 2016 to set out the 
priorities for the life sciences sector that the UK and 
EU Governments must consider in order to ensure 
that patients and public health continue to be well 
served by our medicines, and that in the future, the 
UK can continue to build on its thriving life sciences 
sector for the benefit of innovation and the economy.  
ABPI and BIA reached out to the other trade 
organisations, representing medical technologies 
(devices), diagnostics, clinical research, consumer 
healthcare and animal health (as animal medicines 
are also regulated through the European medicines 
regulatory network).  Our work identified four key 
priorities which was set out in a Ministerial Report in 
early September (see Figure 1): 
1. Long-term, predictable funding for scientific research, 
and continued ability to collaborate at scale 
2. Ability to trade and move goods and capital across 
borders  
3. A common regulatory framework with Europe 
4. Access to the best talent. 
Behind these headings lies a considerable wealth of 
detail and analysis, exploring these requirements for 
our industry under different scenarios and timing 
challenges.  This was not the end of the planning.  
  https://doi.org/10.5920/bjpharm.2017.04 
Acha (2017) BJPharm 2(1), 70-74  72 
We have continued to work through these matters in 
partnership with government and other stakeholders 
ever since and will continue to do so until we have 
clarity on the changes to come. 
The next step in the process has been to engage with 
our European representative organisations to take 
this alignment across the European Member States.     
 
Fig. 1. Life Sciences industry, led by ABPI and BIA, report to 
Ministers to set out the needs for medicines and public health 
(ABPI 2016). 
Engagement across Europe is fundamental to 
consider a new future for medicines discovery, 
development and manufacture and the new markets 
and regulatory systems that will emerge.  Certainly 
the “Day 1” impacts of Brexit are at the forefront of 
our work and discussions today to ensure that, at 
least for the supply of medicines, the day of 
departure for the UK does not impact upon the 
patient.  However, engagement across Europe is also 
needed to define how regulation will be pursued.  As 
discussed earlier, a series of crises (in the case of 
thalidomide in the 1960s) prompted the development 
of the world’s most successful cooperation for 
harmonised regulation in medicines; the question 
now is what will Brexit evoke next in the evolution of 
this regulatory system? 
HARMONISATION OR CONVERGENCE? 
Looking to the future for European regulation, we 
have argued as an industry that cooperation should 
continue.  By cooperation, we are really calling for a 
continuation of the harmonisation in regulation that 
has been established over the previous decades. Such 
harmonisation allows for a free flow in research, 
manufacturing and supply that will ensure that 
European patients – both EU and UK – will continue 
to benefit from innovation in the most 
straightforward way, that industry will benefit from 
streamlined regulation and that European regulation 
itself will continue to move in a progressive and 
innovative way with full capabilities and capacity. 
The question is, what will happen to European 
regulation if cooperation is not possible?  How will 
UK regulation and European Union regulation 
evolve from the closely harmonised and even unified 
(centralised) structures we have today? 
One possibility is that in future, the British and EU 
regulatory systems move to a process of regulatory 
convergence.  Regulatory convergence is a “process 
whereby regulatory requirements across economies 
become more similar or aligned over time as a result 
of gradual adoption of internationally recognised 
technical guidance documents and standards” 
(Tominaga 2015).    Generally speaking, the process 
of regulatory convergence is one that countries go to 
on a path towards harmonisation; however, 
regulatory harmonisation may not be an ultimate 
goal for some countries as they may not be able to 
engage in the legal harmonisation that underpins 
these technical requirements. 
There is little precedent for countries to re-establish 
convergence, after they have been 
unified/harmonised in regulatory policies and 
shared the regulatory work across their systems.  For 
the UK and for the EU medicines regulatory 
network, this is a novel challenge.  We may 
anticipate that both the UK and the EU regulatory 
systems will continue to align to the standards and 
the guidelines of the International Council for 
Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH).  Certainly, 
the EMA and the EU medicines regulatory network 
will continue to participate as Founding Regulatory 
Members of ICH.  The UK’s regulator, the MHRA, 
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will need to apply to become a Regulatory Member 
upon the UK’s departure of the EU, when it will no 
longer be directly represented by the European 
Commission. 
We also know that the regulation as established 
through standing European law (EU acquis) will be 
brought into UK law through the Great Repeal Bill. 
(Davis and May 2017).  In that regard, we expect the 
UK regulatory policies to remain harmonised with 
EU regulations, at least in the short term.  The 
conduct and practice of those policies – e.g. the UK 
regulatory system – should largely mirror what is 
undertaken in Europe, but within the UK agencies, 
including MHRA, the Health Research Authority 
(HRA), the Human Tissue Authority (HTA) and 
others.  The details of these arrangements are greatly 
anticipated, and industry has urged the UK 
Government to clarify its arrangements as soon as 
possible.  The EU and the European Medicines 
Agency have already started to set out the 
requirements for marketing authorisation holders  to 
be prepared to operate in the EU/EEA following the 
UK exit and status thereafter as a third country 
(CMDh 2017a,b; EMA 2017b,c). 
CONCLUSIONS 
This article is titled “Breaking up the band” because 
it reflects both (1) the unique and productive 
cooperation that has been established over decades 
in the European medicines regulatory network and 
(2) the view that it has been the diversity and 
combination of areas of scientific expertise and 
creative approach to regulatory science that has 
really made this a unique partnership.  Finally, it also 
reflects a concern that both the UK and the EU 
medicines regulatory system may be diminished – at 
least for a while – because of this sort of upheaval, 
and that this is clearly to the detriment of supporting 
innovation in medicines and benefit for all European 
patients. 
As any good music fan, therefore, the author is still 
hopeful that the “band will not break up” after all.  
We believe that there is a clear imperative to pursue 
continued regulatory cooperation across the UK and 
the EU, and that there is also a means of doing so, if 
the will is there. 
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